ST14 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL850682	1.00	20/20
SCHEMBL851135	1.00	20/20
SCHEMBL851202	1.00	20/20
SCHEMBL851345	1.00	20/20
SCHEMBL851403	1.00	20/20
SCHEMBL851438	1.00	20/20
SCHEMBL851249	0.93	20/20
SCHEMBL851335	0.91	20/20
SCHEMBL851369	0.89	20/20
SCHEMBL851015	0.87	20/20
SCHEMBL850912	0.87	20/20
SCHEMBL850952	0.86	20/20
SCHEMBL851257	0.85	20/20
SCHEMBL851044	0.83	20/20
SCHEMBL851235	0.82	20/20
SCHEMBL851396	0.82	20/20
SCHEMBL850814	0.80	20/20
SCHEMBL850994	0.78	20/20
SCHEMBL851133	0.77	20/20
SCHEMBL851064	0.76	20/20

Clinical trials — most relevant to ST14 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	PHASE2/PHASE3	RECRUITING
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia	PHASE2	COMPLETED
Phase II Dasatinib Study in Advanced Breast Cancer	PHASE2	COMPLETED
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma	PHASE2	UNKNOWN
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma	PHASE2	COMPLETED
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)	PHASE1/PHASE2	COMPLETED
Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease	PHASE2	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors	PHASE1	COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma	PHASE1	COMPLETED
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201	PHASE1	RECRUITING
Early Diagnosis and Prognosis of Postoperative Sepsis by Presepsin and Syndecan-1	nan	UNKNOWN
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan	nan	UNKNOWN
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma	nan	UNKNOWN
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients	nan	COMPLETED
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy	nan	RECRUITING
Validation of 70-gene MammaPrint Profile in Japanese Population	nan	COMPLETED
Biomarkers of Lichen Sclerosus	nan	UNKNOWN
Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy	nan	UNKNOWN
Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder	nan	COMPLETED
Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.	nan	RECRUITING
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy	nan	COMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)	nan	COMPLETED
Prophylactic Salpingectomy for the Prevention of the Ovarian Cancer: Comparison Between Surgical Techniques	nan	COMPLETED
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Comparison Between the Progostic Value of the Procalcitonin and the Platelet/Total Leukocytic Count Ratio in Sepsis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ST14 binder may also engage these)

Protein	Name	Similarity
P56677	—	1.000	P56677 →
Q0IIH7	—	1.000	Q0IIH7 →
Q3UZ09	—	0.995	Q3UZ09 →
Q5R8J0	—	0.995	Q5R8J0 →
Q5R544	—	0.994	Q5R544 →
Q4R577	—	0.993	Q4R577 →
F7	Coagulation factor VII	0.993	landscape →
P11214	—	0.993	P11214 →
P49150	—	0.993	P49150 →
Q5R1W3	—	0.993	Q5R1W3 →
Q7RTY8	—	0.993	Q7RTY8 →
Q8CFG9	—	0.993	Q8CFG9 →
Q8CG16	—	0.993	Q8CG16 →
TMPRSS4	Transmembrane protease serine 4	0.993	landscape →
P19637	—	0.992	P19637 →
P04185	—	0.992	P04185 →
P86091	—	0.992	P86091 →
Q6IE64	—	0.992	Q6IE64 →
Q5E9P5	—	0.992	Q5E9P5 →
Q5G265	—	0.992	Q5G265 →
Q8BIK6	—	0.992	Q8BIK6 →
P98121	—	0.991	P98121 →
Q20176	—	0.991	Q20176 →
P57727	—	0.991	P57727 →
P31394	—	0.991	P31394 →
Q2F9P2	—	0.991	Q2F9P2 →
Q9UL52	—	0.991	Q9UL52 →
Q9JIQ8	—	0.990	Q9JIQ8 →
TMPRSS15	Enteropeptidase	0.990	landscape →
Q8SQ23	—	0.990	Q8SQ23 →